Crotamine-based recombinant immunotoxin targeting HER2 for enhanced cancer cell specificity and cytotoxicity

Area of Science:

• Biochemistry and Molecular Biology
• Oncology
• Immunology

Background:

• Crotamine, a toxin from South American rattlesnake venom, shows cytotoxic potential for cancer therapy but lacks cancer cell selectivity.
• Improving the targeting of cytotoxic agents to cancer cells is crucial for effective cancer treatment.

Purpose of the Study:

• To design and produce a novel recombinant immunotoxin, HER2(scFv)-CRT, by linking crotamine to a trastuzumab-derived single-chain variable fragment (scFv) targeting HER2.
• To evaluate the specificity and cytotoxicity of HER2(scFv)-CRT in HER2-expressing breast cancer cell lines.

Main Methods:

• Recombinant immunotoxin HER2(scFv)-CRT was expressed in Escherichia coli and purified using chromatographic techniques.
• Cytotoxicity assays were performed on three breast cancer cell lines to assess the efficacy of HER2(scFv)-CRT.

Main Results:

• The recombinant immunotoxin HER2(scFv)-CRT demonstrated enhanced specificity and potent cytotoxicity against HER2-expressing breast cancer cells.
• The study successfully produced and purified the novel immunotoxin.

Conclusions:

• The crotamine-based recombinant immunotoxin HER2(scFv)-CRT shows promise as a targeted cancer therapy agent.
• This novel immunotoxin has the potential to broaden the applications of recombinant immunotoxins in cancer treatment.